Affiliated Caner Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong 510095, China.
Department of Thoracic Surgery, Huiqiao Medical Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
ACS Appl Bio Mater. 2021 Jun 21;4(6):5222-5230. doi: 10.1021/acsabm.1c00386. Epub 2021 May 12.
Mitochondria are identified as a valuable target for cancer therapy owing to their primary function in energy supply and cellular signal regulation. Mitochondria in tumor cells are depicted by excess reactive oxygen species (ROS), which lead to numerous detrimental results. Hence, mitochondria-targeting ROS-associated therapy is an optional therapeutic strategy for cancer. In this contribution, a light-induced ROS generator (TBTP) is developed for evaluation of the efficacy of mitochondria-targeting ROS-associated therapy and investigation of the mechanism underlying mitochondrial-injure-mediated therapy of tumors. TBTP serves as an efficient ROS generator with low cytotoxicity, favorable biocompatibility, excellent photostability, mitochondria-targeted properties, and NIR emission. and experiments reveal that TBTP exhibits effective anticancer potential. ROS generated from TBTP could destroy the integrity of mitochondria, downregulate ATP, decrease the mitochondrial membrane potential, secrete Cyt-c into cytoplasm, activate Caspase-3/9, and induce cell apoptosis. Moreover, RNA-seq analysis highlights that an ROS burst in mitochondria can kill tumor cells via inhibition of the AKT pathway. All these results prove that mitochondrial-targeted ROS-associated therapy hold great potential in cancer therapy.
线粒体由于其在能量供应和细胞信号调节中的主要功能,被认为是癌症治疗的一个有价值的靶点。肿瘤细胞中的线粒体表现为过量的活性氧(ROS),这导致了许多不利的后果。因此,靶向线粒体 ROS 相关的治疗是癌症的一种可选治疗策略。在本研究中,开发了一种光诱导的 ROS 发生器(TBTP),用于评估靶向线粒体 ROS 相关治疗的疗效,并研究线粒体损伤介导的肿瘤治疗的机制。TBTP 是一种高效的 ROS 发生器,具有低细胞毒性、良好的生物相容性、优异的光稳定性、靶向线粒体的特性和近红外发射。体外和体内实验表明,TBTP 具有有效的抗癌潜力。TBTP 产生的 ROS 可以破坏线粒体的完整性,下调 ATP,降低线粒体膜电位,将 Cyt-c 分泌到细胞质中,激活 Caspase-3/9,并诱导细胞凋亡。此外,RNA-seq 分析强调,线粒体中的 ROS 爆发可以通过抑制 AKT 通路杀死肿瘤细胞。所有这些结果证明,靶向线粒体 ROS 相关的治疗在癌症治疗中具有巨大的潜力。